Abstract
We have learned various data on the role of purinoceptors (P2X4, P2X7, P2Y6 and P2Y12 receptors) expressed in spinal microglia and several factors that presumably activate microglia in neuropathic pain after peripheral nerve injury. Especially P2X4 receptors (P2X4Rs) make a critical contribution to the pain processing. P2X4Rs of microglia might be promising targets for treating neuropathic pain. A predicted therapeutic benefit of interfering with microglial P2X4Rs may be that normal pain sensitivity would be unaffected since expression or activity of most of these receptors are upregulated or enhanced predominantly in activated microglia in the spinal cord where damaged sensory fibers project. Recently, we found that CCL21 regulates the expression of P2X4Rs in different manners, respectively. These new findings also provide novel targets for developing anti-neuropathic pain medicines.
Keywords: P2X4Rs, microglia, neuropathic pain, P2X4Rs, microglia, neuropathic pain, Atomic force microscopy, Brain-derived neurotrophic factor, Chemokine (C-C) ligand 2, Central nervous system, Dorsal root ganglion, Anion reversal potential, Eukaryotic translation initiation factor 4E
CNS & Neurological Disorders - Drug Targets
Title:P2X4 Receptors of Microglia in Neuropathic Pain
Volume: 11 Issue: 6
Author(s): Kazuhide Inoue and Makoto Tsuda
Affiliation:
Keywords: P2X4Rs, microglia, neuropathic pain, P2X4Rs, microglia, neuropathic pain, Atomic force microscopy, Brain-derived neurotrophic factor, Chemokine (C-C) ligand 2, Central nervous system, Dorsal root ganglion, Anion reversal potential, Eukaryotic translation initiation factor 4E
Abstract: We have learned various data on the role of purinoceptors (P2X4, P2X7, P2Y6 and P2Y12 receptors) expressed in spinal microglia and several factors that presumably activate microglia in neuropathic pain after peripheral nerve injury. Especially P2X4 receptors (P2X4Rs) make a critical contribution to the pain processing. P2X4Rs of microglia might be promising targets for treating neuropathic pain. A predicted therapeutic benefit of interfering with microglial P2X4Rs may be that normal pain sensitivity would be unaffected since expression or activity of most of these receptors are upregulated or enhanced predominantly in activated microglia in the spinal cord where damaged sensory fibers project. Recently, we found that CCL21 regulates the expression of P2X4Rs in different manners, respectively. These new findings also provide novel targets for developing anti-neuropathic pain medicines.
Export Options
About this article
Cite this article as:
Inoue Kazuhide and Tsuda Makoto, P2X4 Receptors of Microglia in Neuropathic Pain, CNS & Neurological Disorders - Drug Targets 2012; 11 (6) . https://dx.doi.org/10.2174/187152712803581065
DOI https://dx.doi.org/10.2174/187152712803581065 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Bone Morphogenetic Protein-Smad Pathway as Drug Targets for Osteoporosis and Cancer Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Nucleic Acid Carrier Systems Based on Polyethylenimine Conjugates for the Treatment of Metastatic Tumors
Current Medicinal Chemistry CB1 Cannabinoid Receptors and their Associated Proteins
Current Medicinal Chemistry Progress in Small Molecule Therapeutics for the Treatment of Retinoblastoma
Mini-Reviews in Medicinal Chemistry Alpha-1-Adrenergic Receptor Blockade Modifies Insulin-Regulated Aminopeptidase (IRAP) Activity in Rat Prostate and Modulates Oxytocin Functions
Drug Metabolism Letters Clostridial Neurotoxins: Mode of Substrate Recognition and Novel Therapy Development
Current Protein & Peptide Science Anaplastic Lymphoma Kinase as a Therapeutic Target in Anaplastic Large Cell Lymphoma, Non-Small Cell Lung Cancer and Neuroblastoma
Anti-Cancer Agents in Medicinal Chemistry Expression, Distribution and Regulation of Phosphodiesterase 5
Current Pharmaceutical Design Amine Oxidase Inhibitors and Development of Neuroprotective Drugs
Current Neuropharmacology Critical Questions for Preclinical Trials on Safety and Efficacy of Vascular Endothelial Growth Factor-Based Therapeutic Angiogenesis for Ischemic Stroke
CNS & Neurological Disorders - Drug Targets Roles of EGFR, PI3K, AKT, and mTOR in Heavy Metal-Induced Cancer
Current Cancer Drug Targets Threes Company: Regulation of Cell Fate by Statins
Current Drug Targets - Cardiovascular & Hematological Disorders Therapeutic microRNA Delivery Strategies with Special Emphasis on Cancer Therapy and Tumorigenesis: Current Trends and Future Challenges
Current Drug Metabolism Erythropoietin and Oxidative Stress
Current Neurovascular Research Targeting ADAM17 Sheddase Activity in Cancer
Current Drug Targets NAMPT in Regulated NAD Biosynthesis and its Pivotal Role in Human Metabolism
Current Medicinal Chemistry The Role of Components of the Lymphoreticular System in Transmissible Spongiform Encephalopathy Pathogenesis and Neuroinvasion
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Hyperglycemia, Hypoglycemia and Dementia: Role of Mitochondria and Uncoupling Proteins
Current Molecular Medicine Mechanisms of Melatonin in Alleviating Alzheimer’s Disease
Current Neuropharmacology Antiproliferative Activity of microRNA-125a and its Molecular Targets
MicroRNA